Lymfactin(TM) Found to Significantly Increase Growth of Lymphatic Vessels in Animal Study; Results Seen as "Pathway to a Breakthrough" for Breast Cancer Patients Who Would Benefit From Lymph Node Transfers for Lymphedema
23. September 2011 05:00 ET | Laurantis Pharma
MALMO, SWEDEN--(Marketwire - Sep 23, 2011) - Laurantis Pharma, a privately held biotechnology company based in Finland, today announced that Lymfactin™, adenoviral VEGF-C growth factor...